Mangalam Drugs & Organics Limited (BOM:532637)
27.00
-0.50 (-1.82%)
At close: Jul 28, 2026
Mangalam Drugs & Organics Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 427 | 439 | 1,175 | 1,466 | 1,549 | 1,628 | |
Market Cap Growth | -69.72% | -62.63% | -19.89% | -5.31% | -4.86% | 3.47% |
Enterprise Value | 1,547 | 1,420 | 2,108 | 2,355 | 2,372 | 2,383 |
Last Close Price | 27.00 | 27.74 | 74.22 | 92.65 | 97.85 | 102.85 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | 17.48 | - | 121.95 | 8.28 |
PS Ratio | 0.18 | 0.19 | 0.37 | 0.40 | 0.42 | 0.36 |
PB Ratio | 0.41 | 0.43 | 0.79 | 1.08 | 1.02 | 1.08 |
P/TBV Ratio | 0.61 | 0.63 | 0.82 | 1.19 | 1.16 | 1.19 |
P/FCF Ratio | - | - | 5.25 | - | 13.34 | - |
P/OCF Ratio | 10.23 | 10.51 | 2.76 | 37.48 | 3.92 | 6.33 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 0.67 | 0.61 | 0.66 | 0.64 | 0.64 | 0.53 |
EV/EBITDA Ratio | - | - | 6.39 | 30.65 | 9.84 | 5.03 |
EV/EBIT Ratio | - | - | 10.78 | 84.17 | 16.21 | 6.14 |
EV/FCF Ratio | - | - | 9.41 | - | 20.43 | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 1.09 | 1.09 | 0.65 | 0.79 | 0.58 | 0.58 |
Debt / EBITDA Ratio | - | - | 2.74 | 11.42 | 3.53 | 1.81 |
Debt / FCF Ratio | - | - | 4.30 | - | 7.63 | - |
Net Debt / Equity Ratio | 1.09 | 1.09 | 0.63 | 0.78 | 0.56 | 0.57 |
Net Debt / EBITDA Ratio | -7.92 | -7.92 | 2.84 | 13.77 | 3.56 | 1.82 |
Net Debt / FCF Ratio | -14.50 | -14.50 | 4.18 | -13.36 | 7.40 | -43.85 |
Asset Turnover | 0.68 | 0.68 | 0.91 | 1.06 | 1.08 | 1.52 |
Inventory Turnover | 1.30 | 1.30 | 1.30 | 1.89 | 1.99 | 3.53 |
Quick Ratio | 0.21 | 0.21 | 0.22 | 0.18 | 0.30 | 0.37 |
Current Ratio | 0.79 | 0.79 | 1.04 | 1.07 | 1.25 | 1.42 |
Return on Equity (ROE) | -35.23% | -35.23% | 4.72% | -6.30% | 0.84% | 13.97% |
Return on Assets (ROA) | -5.94% | -5.94% | 3.49% | 0.50% | 2.66% | 8.19% |
Return on Invested Capital (ROIC) | -14.69% | -14.14% | 8.08% | 1.17% | 3.54% | 12.60% |
Return on Capital Employed (ROCE) | -27.30% | -27.30% | 11.20% | 1.60% | 7.50% | 19.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -103.89% | -101.12% | 5.72% | -6.19% | 0.82% | 12.07% |
FCF Yield | -18.07% | -17.59% | 19.06% | -5.40% | 7.50% | -1.20% |
Buyback Yield / Dilution | -0.00% | -0.00% | - | - | - | - |
Total Shareholder Return | -0.00% | -0.00% | - | - | - | - |